JAMA Psychiatry
August 24, 2022
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al.
668 citations
Two doses of psilocybin, given alongside psychotherapy, substantially reduced heavy drinking in people with alcohol use disorder compared to an active placebo (diphenhydramine) plus psychotherapy. Over 32 weeks, heavy drinking days averaged 9.7% in the psilocybin group versus 23.6% in the placebo group—a mean difference of 13.9 percentage points. Daily alcohol consumption was also lower with psilocybin. No serious adverse events occurred in the psilocybin group. The findings support further research into psilocybin-assisted treatment for alcohol use disorder.
Experimental and Clinical Psychopharmacology
November 27, 2023
Jakub Greń, Ingmar Gorman, Anastasia Ruban et al.
27 citations
Psychedelic integration (PI) refers to practices that aim to minimize harms or maximize benefits after psychedelic use. Although PI is considered essential in psychedelic-assisted therapy, existing models lack empirical support and are not evidence-based. With psychedelic use increasing, the article calls for scientific efforts to develop, examine, and evaluate PI methods. It summarizes current literature, suggests research avenues, and discusses limitations and challenges of PI-focused research.
American Journal of Psychiatry
January 1, 2025
Noam Goldway, Snehal Bhatt, Stephen Ross et al.
23 citations
Psilocybin-assisted therapy (PAT) produced lasting changes in personality, indicating a normalization of abnormal personality trait expression in people with alcohol use disorder. The findings suggest that PAT may reduce impulsiveness, or that impulsive individuals may inherently respond better to the therapy. Further research is needed to clarify the mechanism.
Frontiers in Pharmacology
June 27, 2022
Snehal Bhatt, Maya Armstrong, Tassy Parker et al.
4 citations
Post-traumatic stress disorder (PTSD) and substance use disorders (SUDs) frequently co-occur, a link shaped by adverse childhood experiences, historical and multi-generational traumas, and social, cultural, and spiritual factors. Current treatments for PTSD are only modestly effective, and more research is needed on interventions for co-occurring PTSD and SUD, including whether to treat them together or sequentially. Interest in psychedelics as a treatment augmentation is reviving, though risks remain. This review covers the history of psychedelic research and practices, examining historical trauma, adverse childhood experiences, PTSD, and SUDs through the lens of New Mexico, a state with large Indigenous and Hispanic populations and high rates of trauma and substance use. Future directions include community-based participatory approaches respectful of Indigenous and minority communities.